| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| VBI Vaccines Inc. | Sci-B-Vac - (PROTECT) | Hepatitis B vaccine | Phase 3 | Intramuscular | Immunology | |
| VBI Vaccines Inc. | VBI-1901 | Recurrent glioblastoma multiforme (rGBM) | Phase 2b | Data Released | Intramuscular | Oncology |
| VBI Vaccines Inc. | BRII-835 (VIR-2218) and BRII-179 (VBI-2601) | Hepatitis B | Phase 2 | Data Released | Subcutaneous | Antiviral |
| VBI Vaccines Inc. | BRII-179 (VBI-2601) with PEG-IFN-α | Hepatitis B | Phase 2 | Data Released | Intramuscular | Antiviral |
| VBI Vaccines Inc. | BRII-835 (VIR-2218) and BRII-179 (VBI-2601) | Hepatitis B | Phase 2 | Data Released | Subcutaneous | Antiviral |
| VBI Vaccines Inc. | BRII-179 (VBI-2601) with PEG-IFN-α | Hepatitis B | Phase 2 | Data Released | Intramuscular | Antiviral |
| Ventyx Biosciences Inc. | VTX2735 | Healthy volunteers, cryopyrin-associated periodic syndrome (CAPS) | Phase 2 | Ongoing | oral | Genetic Disorder |
| Ventyx Biosciences Inc. | VTX3232 | Obesity and cardiometabolic risk factors | Phase 2 | Data Released | Oral | Endocrinology |